Locally Advanced/Metastatic Solid Tumors
Conditions
Keywords
Methionine adenosyltransferase 2A (MAT2A), homozygous MTAP deletion, MAT2A inhibitor, ISM3412
Brief summary
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
Interventions
DRUGISM3412
ISM3412 will be administered orally once daily.
Sponsors
InSilico Medicine Hong Kong Limited
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female participants with age ≥18 years at the time of signing the informed consent. 2. Histologically confirmed unresectable locally advanced or metastatic solid tumors with confirmed homozygous MTAP deletion, who have disease progression after standard therapy, intolerable to standard therapy, or for whom no standard therapy exists. 3. Have measurable or evaluable lesions in Part 1 and at least one measurable target lesion in Part 2 as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. 4. ECOG PS (Eastern Cooperative Oncology Group Performance Status) ≤1. 5. Life expectancy of ≥12 weeks as judged by the investigator. 6. Adequate organ function as determined by medical assessment. 7. Capable of providing signed ICF and complying with the requirements and restrictions listed in the ICF and in this study protocol.
Exclusion criteria
1. Prior treated with other MAT2A inhibitors and/or PRMT inhibitors. 2. Participation in other therapeutic clinical studies within 28 days or 5 half-lives (whichever is shorter) prior to first dose of study treatment. 3. Anti-tumor therapy (chemotherapy, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or other anti-tumor therapy, except for hormones for hypothyroidism or estrogen replacement therapy, anti-estrogen analogues, agonists required to suppress serum testosterone levels) within 28 days or 5 half-lives, whichever is shorter prior to first dose of study treatment. 4. Toxicities of prior therapy have not resolved to Grade ≤1 or to baseline (as evaluated by NCI CTCAE version 5.0) 5. History of another primary tumor that has been diagnosed or required therapy within the past 3 years. 6. Previous history of, or presence of Gilbert's syndrome. 7. Previous history of myelodysplastic syndrome. 8. Prior solid organ or hematopoietic stem cell transplant. 9. Known active central nervous system (CNS) primary tumor or untreated CNS metastases. 10. Have serious cardiovascular or cerebrovascular disease as per protocol. 11. Presence of uncontrolled systemic infection as per protocol. 12. Unwillingness or unable to comply with the requirements of oral drug administration, or presence of a gastro-intestinal condition. Other protocol inclusion and
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of dose-limiting toxicity (DLT) events | 31 days | To evaluate the safety and tolerability of ISM3412. |
| Incidence and severity of adverse events (AEs) | Approximately 30 months | To evaluate the safety and tolerability of ISM3412. |
| Recommended phase 2 dose (RP2D) | Approximately 30 months | To determine the RP2D of ISM3412. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum observed concentration (Cmax) | Approximately 30 months | To assess PK of ISM3412 in plasma following a single and multiple doses of ISM3412 |
| Time of maximum observed concentration (Tmax) | Approximately 30 months | To assess PK of ISM3412 in plasma following a single and multiple doses of ISM3412 |
| Area under the concentration-time curve (AUC) | Approximately 30 months | To assess PK of ISM3412 in plasma following a single and multiple doses of ISM3412 |
| Terminal half-life (t1/2) | Approximately 30 months | To assess PK of ISM3412 in plasma following a single and multiple doses of ISM3412 |
| Objective response rate (ORR) | Approximately 30 months | To evaluate the preliminary efficacy of ISM3412 in participants with locally advanced/metastatic solid tumors. |
| Best objective response (BOR) | Approximately 30 months | To evaluate the preliminary efficacy of ISM3412 in participants with locally advanced/metastatic solid tumors. |
| Duration of response (DoR) | Approximately 30 months | To evaluate the preliminary efficacy of ISM3412 in participants with locally advanced/metastatic solid tumors. |
Countries
China, United States
Contacts
CONTACTJohnny Ju
Outcome results
None listed